Christian Fulda

Jones Day (Munich)
Lawyer (Partner)

Dr. Christian Fulda focuses his practice on the pharmaceutical, biotechnology, and medical device industries. He has broad experience covering the legal issues that these heavily regulated industries face, including product development and issues related to securing IP rights; entering into development agreements and setting up clinical trials; advising on regulatory questions regarding marketing authorizations and reimbursement; negotiating manufacturing and distribution and related agreements; accompanying the development and implementation of digital health and telehealth applications, including related data privacy issues; and advising on day-to-day operations, including advertising regulation, health care compliance, and product liability issues. Christian routinely carries out multijurisdictional projects for life sciences clients. He also assists clients in M&A transactions in these industries. In addition, Christian has an extensive track record in global dispute matters, covering injunction and main proceedings before state courts in cross-jurisdictional litigations and in international arbitrations. Christian is a Fellow of the International Institute for Law and Medicine and a member of BIO Germany (Regulatory Affairs Committee and Healthcare Policy Committee), Licensing Executives Society Germany (Life Sciences Working Group), the Federal Association of Pharmaceutical Manufacturers (BAH), Forum MedTech Pharma, the Middle-European Society for Regulatory Affairs (MEGRA), and the German Institution of Arbitration (DIS).

Linked authors

Jones Day (Milano)
Jones Day (Paris)

Articles

179 Bulletin

Christian B. Fulda, Lamberto Schiona, Ozan Akyurek The Italian Supreme Court upholds the class action ruling of the Court of Appeal of Milan on misleading advertising (Voden)

179

The Situation: On January 31, 2018, the Italian Supreme Court ruled on the first Italian product-related class action promoted by a consumers’ association. The Result: The Court upheld the consumer’s class action claim regarding the unlawful advertising of a medical device. Looking Ahead: The (...)

Send a message